Clinical Trial Update: Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) [Phase 2]

View source ↗

Summary

BioAegis Therapeutics is sponsoring a Phase 2 trial of Rhu-pGSN (recombinant human plasma gelsolin) for acute respiratory distress syndrome, with recruitment on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Rhu-pGSN (recombinant human plasma gelsolin)

Snippet

Sponsor: BioAegis Therapeutics Inc. | Conditions: Acute Respiratory Distress Syndrome, Infections | Phase 2 | Status: RECRUITING